Moving away from systematic biopsies: image-guided prostate biopsy (in-bore biopsy, cognitive fusion biopsy, MRUS fusion biopsy) -literature review.

Abstract

OBJECTIVE:

To compare the detection rate of clinically significant cancer (CSCa) by magnetic resonance imaging-targeted biopsy (MRI-TB) with that by standard systematic biopsy (SB) and to evaluate the role of MRI-TB as a replacement from SB in men at clinical risk of prostate cancer.

METHODS:

The non-systematic literature was searched for peer-reviewed English-language articles using PubMed, including the prospective paired studies, where the index test was MRI-TB and the comparator text was SB. Also the randomized clinical trials (RCTs) are included if one arm was MRI-TB and another arm was SB.

RESULTS:

Eighteen prospective studies used both MRI-TB and TRUS-SB, and eight RCT received one of the tests for prostate cancer detection. In most prospective trials to compare MRI-TB vs. SB, there was no significant difference in any cancer detection rate; however, MRI-TB detected more men with CSCa and fewer men with CISCa than SB.

CONCLUSION:

MRI-TB is superior to SB in detection of CSCa. Since some significant cancer was detected by SB only, a combination of SB with the TB technique would avoid the underdiagnosis of CSCa.

• Authors: Yasuhiro Yamada, Osamu Ukimura, Masatomo Kaneko, Toru Matsugasumi, Atsuko Fujihara, Srinivas Vourganti, Leonard Marks, Abhinav Sidana, Laurence Klotz, Georg Salomon, Jean de la Rosette
• Journal: World journal of urology (World J Urol) Vol. 39 Issue 3 Pg. 677-686 (Mar 2021) ISSN: 1433-8726 [Electronic] Germany
• PMID: 32728885 (Publication Type: Comparative Study, Journal Article, Review)

Topics

• Biopsy (methods)
• Humans
• Image-Guided Biopsy
• Magnetic Resonance Imaging, Interventional
• Male
• Prostate (pathology)
• Prostatic Neoplasms (pathology)
• Ultrasonography, Interventional